Skip to main content
Download PDF
- Main
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial.
- Branche, Angela;
- Rouphael, Nadine;
- Losada, Cecilia;
- Baden, Lindsey;
- Anderson, Evan;
- Luetkemeyer, Anne;
- Diemert, David;
- Winokur, Patricia;
- Presti, Rachel;
- Kottkamp, Angelica;
- Falsey, Ann;
- Frey, Sharon;
- Rupp, Richard;
- Bäcker, Martín;
- Novak, Richard;
- Walter, Emmanuel;
- Jackson, Lisa;
- Immergluck, Lilly;
- Mahgoub, Siham;
- Whitaker, Jennifer;
- Babu, Tara;
- Goepfert, Paul;
- Fusco, Dahlene;
- Atmar, Robert;
- Posavad, Christine;
- Netzl, Antonia;
- Smith, Derek;
- Telu, Kalyani;
- Mu, Jinjian;
- Makowski, Mat;
- Makhene, Mamodikoe;
- Crandon, Sonja;
- Montefiori, David;
- Roberts, Paul;
- Beigel, John;
- Little, Susan
- et al.
Published Web Location
https://doi.org/10.1093/cid/ciad209Abstract
In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wild-type spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.
Main Content
For improved accessibility of PDF content, download the file to your device.
Enter the password to open this PDF file:
File name:
-
File size:
-
Title:
-
Author:
-
Subject:
-
Keywords:
-
Creation Date:
-
Modification Date:
-
Creator:
-
PDF Producer:
-
PDF Version:
-
Page Count:
-
Page Size:
-
Fast Web View:
-
Preparing document for printing…
0%